Screener
Janux Therapeutics JANX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's accounts payable?
- Janux Therapeutics (JANX) reported accounts payable of $3.02M in Q2 2026.
- How has Janux Therapeutics's accounts payable changed year-over-year?
- Janux Therapeutics's accounts payable decreased by 13.2% year-over-year, from $3.48M to $3.02M.
- What is the long-term trend for Janux Therapeutics's accounts payable?
- Over 4 years (2021 to 2025), Janux Therapeutics's accounts payable has grown at a 20.3% compound annual growth rate (CAGR), from $6.77M to $14.19M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Janux Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude